UBS Downgrades Medpace Hldgs to Neutral, Lowers Price Target to $350

Benzinga · 09/27 14:10
UBS analyst Dan Leonard downgrades Medpace Hldgs (NASDAQ:MEDP) from Buy to Neutral and lowers the price target from $420 to $350.